Today: 10 April 2026
Subscribe
Browse Category

NYSE:KVUE 14 October 2025 - 4 November 2025

Kenvue (NYSE: KVUE) Stock Surges on $40B Buyout – Spin‑Off Saga, Tylenol Turmoil & Investor Outlook

Kenvue (NYSE: KVUE) Stock Surges on $40B Buyout – Spin‑Off Saga, Tylenol Turmoil & Investor Outlook

Kimberly-Clark agreed to acquire Kenvue for $48.7 billion on Nov. 3, 2025, a 46% premium to its prior close. Kenvue shares surged nearly 20% on the news, while Kimberly-Clark stock dropped 13%. The deal follows a turbulent year for Kenvue, including a CEO ouster, falling sales, and litigation over Tylenol safety claims. Kenvue posted $15 billion in 2025 revenue and maintained gross margins near 59%.
4 November 2025
···
Kimberly-Clark’s $40 Billion Gamble Sends KMB Stock Plunging – What’s Next for This Dividend King?

Kimberly-Clark’s $40 Billion Gamble Sends KMB Stock Plunging – What’s Next for This Dividend King?

Kimberly-Clark shares plunged 14.6% on Nov. 3 to a 52-week low near $102 after announcing a $40 billion cash-and-stock deal to acquire Kenvue at a 46% premium. The drop erased about 15% of KMB’s market value, with the stock now down 21% year-over-year. Investors cited concerns over Kenvue’s litigation risks and debt load. KMB trades at 17.3× earnings, with a 4.9% dividend yield.
4 November 2025
··
Kenvue (KVUE) Stock Soars 20% on $48.7 B Buyout News – Q3 Earnings Beat and What’s Next

Kenvue (KVUE) Stock Soars 20% on $48.7 B Buyout News – Q3 Earnings Beat and What’s Next

Kimberly-Clark announced a $48.7 billion cash-and-stock deal to acquire Kenvue, sending Kenvue shares up about 20% in pre-market trading to near $17.50. Kenvue shareholders will receive $3.50 in cash and 0.14625 KMB shares per KVUE share. Kenvue reported Q3 net profit of $398 million, beating earnings expectations. Kimberly-Clark shares fell roughly 12.5% on the news.
3 November 2025
····
Kenvue (KVUE) Stock Plummets to Record Low Amid Talc Lawsuit and Tylenol Scare

Kenvue (KVUE) Stock Plummets to Record Low Amid Talc Lawsuit and Tylenol Scare

Kenvue shares plunged 13% Thursday to a record low near $14 after news of U.K. lawsuits over Johnson’s Baby Powder, representing 3,000 claimants and potential £1 billion in damages. The stock is down about 34% year-to-date and nearly 40% below its IPO price. Wall Street cut price targets and Moody’s downgraded its outlook to “negative.” Kenvue’s market cap now stands at roughly $30–31 billion.
17 October 2025
···
Kenvue (KVUE) Stock Plunges Amid Tylenol and Talc Fears – What’s Next?

Kenvue (KVUE) Stock Plunges Amid Tylenol and Talc Fears – What’s Next?

Kenvue shares hit a 52-week low of $15.46 on Oct. 16, 2025, down about 5% in one day and over 27% in the past year. The company faces new UK talcum-powder lawsuits and ongoing FDA scrutiny over Tylenol, while Q2 revenue fell 4% to $3.84 billion. Moody’s affirmed its A1 rating but cut the outlook to negative. Kenvue replaced its CEO in July and launched a strategic review, considering asset sales.
16 October 2025
·
J&J Makes Bold Move: Orthopedics Spin-Off (“DePuy Synthes”) Announced – 2025 Forecast Raised

J&J Makes Bold Move: Orthopedics Spin-Off (“DePuy Synthes”) Announced – 2025 Forecast Raised

Johnson & Johnson will spin off its $9.2 billion orthopedics business as DePuy Synthes within 18–24 months, its second major split since 2023. J&J beat Q3 2025 earnings estimates, raised its full-year revenue outlook to up to $93.9 billion, and saw shares rise 2% on Oct. 14. The move shifts J&J’s focus to higher-growth drug and device segments. CFO Joe Wolk said orthopedics innovation was “in better hands somewhere else.”
14 October 2025
·
1 2 3

Stock Market Today

  • Chubb (CB) Stock Analysis: Undervalued Despite Strong Gains
    April 10, 2026, 6:42 AM EDT. Chubb (CB) has seen robust share price growth, rising over 121% in five years. Despite this, valuation models indicate it remains undervalued by approximately 49.3%. Its current share price around $332.94 contrasts with an intrinsic value estimate near $656. The insurer's Price-to-Earnings ratio of 12.55 exceeds the peer average of 9.07, reflecting expectations of stronger earnings or lower risk. Excess Returns analysis highlights Chubb's capacity to generate profits above shareholder-required returns, supported by a Return on Equity of 13.16%. Investors evaluating Chubb should consider its steady performance, solid market position, and capital strength alongside valuation scores suggesting potential for further upside.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 10.04.2026

10 April 2026
LIVEMarkets rolling coverageStarted: April 10, 2026, 12:00 AM EDTUpdated: April 10, 2026, 6:46 AM EDT Whitestone (WSR) Shares Jump 11.8% on Ares Acquisition News April 10, 2026, 6:46 AM EDT. Whitestone (WSR) shares surged 11.8% to $18.93 driven by increased trading volume following Ares Real Estate Funds' $1.7 billion all-cash acquisition announcement. The real estate investment trust (REIT) is expected to report a quarterly Funds From Operations (FFO) per share of $0.27, up 8% year-over-year, with revenues projected to rise 12.6% to $42.79 million. Despite recent price gains, FFO estimates have been stable for 30 days, suggesting the rally might
MARA Holdings Stock Rises Even After Target Cut as Bitcoin Miner Leans Harder Into AI

MARA Holdings Stock Rises Even After Target Cut as Bitcoin Miner Leans Harder Into AI

9 April 2026
MARA Holdings shares rose 1.7% to $9.67 Thursday despite Cantor Fitzgerald cutting its price target to $10. The company recently sold 15,133 bitcoin for $1.1 billion and agreed to repurchase $1 billion in convertible notes at a discount. MARA is expanding into AI and cloud infrastructure, but fourth-quarter revenue fell 6% and it posted a $1.7 billion net loss.
CoreWeave secures fresh $21 billion Meta AI deal as debt push raises stakes

CoreWeave secures fresh $21 billion Meta AI deal as debt push raises stakes

9 April 2026
Meta Platforms signed a new $21 billion deal with CoreWeave for AI cloud computing capacity through 2032, according to a securities filing. CoreWeave shares rose 3.4% in after-hours trading. The agreement adds to a $14.2 billion commitment disclosed last September. CoreWeave also launched $3 billion in convertible notes and upsized a senior-notes deal to $1.75 billion.
Tesla Revives Cheaper EV Push With New Compact SUV as Sales Pressure Builds

Tesla Revives Cheaper EV Push With New Compact SUV as Sales Pressure Builds

9 April 2026
Tesla is developing a lower-cost compact SUV, with initial production planned for Shanghai, Reuters reported Thursday. The company built 408,386 vehicles and delivered 358,023 in the first quarter, leaving its widest gap in at least four years. Reuters said the new SUV likely will not reach production this year. Tesla did not respond to questions about the project.
NIO ES9 Price Starts at 528,000 Yuan as Flagship SUV Bet Faces China EV Slump

NIO ES9 Price Starts at 528,000 Yuan as Flagship SUV Bet Faces China EV Slump

9 April 2026
NIO opened pre-orders for its ES9 flagship SUV Thursday, pricing it at 528,000 yuan with battery or 420,000 yuan under its Battery-as-a-Service plan. March deliveries rose 136% year-on-year, but NIO’s U.S. shares fell 4.9% after the announcement. The ES9 enters a shrinking premium SUV market in China, competing with Li Auto and Aito. CEO William Li warned chip shortages could add up to 10,000 yuan per vehicle.
Go toTop